Astellas Pharma (OTCMKTS:ALPMY) Upgraded by Zacks Research to “Strong-Buy” Rating

Astellas Pharma (OTCMKTS:ALPMY) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Astellas Pharma Stock Performance

Astellas Pharma stock opened at $13.35 on Tuesday. The firm has a market capitalization of $24.16 billion, a P/E ratio of 12.43 and a beta of 0.07. The stock has a fifty day moving average price of $14.31 and a two-hundred day moving average price of $14.65. Astellas Pharma has a 52-week low of $9.22 and a 52-week high of $17.35. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Monday, April 27th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. The company had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. As a group, analysts anticipate that Astellas Pharma will post 1.34 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).